Castle Biosciences, Inc.

NASDAQ:CSTL

19.29 (USD) • At close March 14, 2025
Bedrijfsnaam Castle Biosciences, Inc.
Symbool CSTL
Munteenheid USD
Prijs 19.29
Beurswaarde 550,036,989
Dividendpercentage 0%
52-weken bereik 16.965 - 35.84
Industrie Diagnostics & Research
Sector Healthcare
CEO Mr. Derek J. Maetzold
Website https://castlebiosciences.com

An error occurred while fetching data.

Over Castle Biosciences, Inc.

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary

Vergelijkbare Aandelen

Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc.

FHTX

4.43 USD

Sangamo Therapeutics, Inc. logo

Sangamo Therapeutics, Inc.

SGMO

0.981 USD

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

23.51 USD

Bioventus Inc. logo

Bioventus Inc.

BVS

9.61 USD

Surmodics, Inc. logo

Surmodics, Inc.

SRDX

28.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)